JP2018516940A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516940A5 JP2018516940A5 JP2017563134A JP2017563134A JP2018516940A5 JP 2018516940 A5 JP2018516940 A5 JP 2018516940A5 JP 2017563134 A JP2017563134 A JP 2017563134A JP 2017563134 A JP2017563134 A JP 2017563134A JP 2018516940 A5 JP2018516940 A5 JP 2018516940A5
- Authority
- JP
- Japan
- Prior art keywords
- cognitive function
- cognitive
- function promoting
- animal subject
- dietary supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 42
- 230000003920 cognitive function Effects 0.000 claims 16
- 230000001737 promoting effect Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 9
- 235000015872 dietary supplement Nutrition 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 claims 5
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical group CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 230000037410 cognitive enhancement Effects 0.000 claims 2
- 230000001143 conditioned effect Effects 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical group CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000005915 GABA Receptors Human genes 0.000 claims 1
- 108010005551 GABA Receptors Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 229940095474 NMDA agonist Drugs 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100000863 loss of memory Toxicity 0.000 claims 1
- 230000006386 memory function Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 229960001685 tacrine Drugs 0.000 claims 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172690P | 2015-06-08 | 2015-06-08 | |
| US62/172,690 | 2015-06-08 | ||
| PCT/US2016/035764 WO2016200690A1 (en) | 2015-06-08 | 2016-06-03 | USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516940A JP2018516940A (ja) | 2018-06-28 |
| JP2018516940A5 true JP2018516940A5 (enExample) | 2019-10-10 |
| JP6851081B2 JP6851081B2 (ja) | 2021-03-31 |
Family
ID=57504356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563134A Active JP6851081B2 (ja) | 2015-06-08 | 2016-06-03 | 認知機能を向上させるためのＨ３Ｋ９ｍｅ３調節の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10272093B2 (enExample) |
| EP (2) | EP3733188B1 (enExample) |
| JP (1) | JP6851081B2 (enExample) |
| KR (1) | KR102776570B1 (enExample) |
| CN (1) | CN107849061B (enExample) |
| AU (2) | AU2016276172B2 (enExample) |
| CA (1) | CA2988568A1 (enExample) |
| ES (2) | ES2944446T3 (enExample) |
| IL (1) | IL256055B (enExample) |
| MX (1) | MX2017015909A (enExample) |
| WO (1) | WO2016200690A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017015909A (es) * | 2015-06-08 | 2018-05-07 | Univ California | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. |
| CN111032025A (zh) * | 2017-06-20 | 2020-04-17 | 居里研究所 | Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途 |
| CN108434454B (zh) * | 2018-03-16 | 2019-10-11 | 大连医科大学 | Adar1在缓解认知功能障碍方面的应用 |
| WO2020223475A1 (en) * | 2019-05-02 | 2020-11-05 | Board Of Regents, The University Of Texas System | Methods and compositions involving tert activating therapies |
| US20240009203A1 (en) * | 2020-08-03 | 2024-01-11 | Cedars-Sinai Medical Center | Compositions and methods for treating alzheimer's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534255B1 (en) * | 2003-01-24 | 2009-05-19 | Photothera, Inc | Low level light therapy for enhancement of neurologic function |
| US20060019227A1 (en) | 2004-07-22 | 2006-01-26 | Hardwicke Susan B | Methods for cognitive treatment |
| CA2601777A1 (en) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP2026783A2 (en) | 2006-06-09 | 2009-02-25 | Wyeth a Corporation of the State of Delaware | Method for enhancing cognitive function |
| JP2009084271A (ja) * | 2007-09-07 | 2009-04-23 | Toyama Univ | 脳由来神経栄養因子の発現誘導剤および発現誘導方法 |
| NZ593447A (en) * | 2008-12-03 | 2012-12-21 | Harvard College | Inhibition of hdac2 to promote memory |
| WO2011109267A1 (en) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| KR101235256B1 (ko) * | 2010-09-13 | 2013-02-21 | 서울대학교산학협력단 | ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료 |
| EP2909214B1 (en) | 2012-10-22 | 2020-07-22 | City of Hope | Etp derivatives |
| CA2909506C (en) * | 2013-04-17 | 2021-04-20 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
| CA3089881C (en) * | 2013-11-26 | 2024-04-02 | University Of North Texas Health Science Center At Fort Worth | Personalized medicine approach for treating cognitive loss |
| MX2017015909A (es) * | 2015-06-08 | 2018-05-07 | Univ California | Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva. |
-
2016
- 2016-06-03 MX MX2017015909A patent/MX2017015909A/es unknown
- 2016-06-03 JP JP2017563134A patent/JP6851081B2/ja active Active
- 2016-06-03 EP EP20172824.3A patent/EP3733188B1/en active Active
- 2016-06-03 ES ES20172824T patent/ES2944446T3/es active Active
- 2016-06-03 CN CN201680040210.0A patent/CN107849061B/zh active Active
- 2016-06-03 AU AU2016276172A patent/AU2016276172B2/en active Active
- 2016-06-03 CA CA2988568A patent/CA2988568A1/en active Pending
- 2016-06-03 US US15/580,419 patent/US10272093B2/en active Active
- 2016-06-03 ES ES16808065T patent/ES2807878T3/es active Active
- 2016-06-03 KR KR1020187000444A patent/KR102776570B1/ko active Active
- 2016-06-03 WO PCT/US2016/035764 patent/WO2016200690A1/en not_active Ceased
- 2016-06-03 EP EP16808065.3A patent/EP3303347B1/en active Active
-
2017
- 2017-12-03 IL IL256055A patent/IL256055B/en unknown
-
2019
- 2019-03-15 US US16/354,996 patent/US10849910B2/en active Active
- 2019-10-11 AU AU2019246902A patent/AU2019246902B2/en active Active
-
2020
- 2020-10-16 US US17/072,539 patent/US11311551B2/en active Active
-
2022
- 2022-03-17 US US17/697,893 patent/US20230057592A1/en not_active Abandoned
-
2024
- 2024-02-14 US US18/441,939 patent/US20240374608A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516940A5 (enExample) | ||
| JP2019048843A5 (enExample) | ||
| JP2015503593A5 (enExample) | ||
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| Shahsavarian et al. | Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway | |
| WO2017141104A8 (en) | Method for inducing a sustained immune response | |
| JP2017528516A5 (enExample) | ||
| RU2017106896A (ru) | Антиметаногенные композиции и их применение | |
| JP2017533220A5 (enExample) | ||
| MA45625A (fr) | Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl | |
| PH12019500516A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| JP2016505050A5 (enExample) | ||
| EP3801539A4 (en) | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF LINAGLIPTIN | |
| Mullaicharam | A review on evidence based practice of Ginkgo biloba in brain health | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制剂的给药方案 | |
| Mastoi et al. | Comparision of antidyslipiemic potential of 80 milligrams of Fenofibrated with 8 grams of Nigella sativa seeds daily | |
| RU2021101120A (ru) | Сублингвальное или буккальное введение dim для лечения заболеваний кожи | |
| ZA202106071B (en) | Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines | |
| WO2019004713A3 (ko) | 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법 | |
| TH1601001257A (th) | องค์ประกอบของยาเม็ดซึ่งแตกตัวทางปากซึ่งมีคอร์ทิโคสเทียรอยด์สำหรับหลอดอาหารอักเสบเหตุอีโอสิโนฟิล | |
| EA201800480A1 (ru) | Бифункциональная композиция для лечения заболеваний опорно-двигательного аппарата | |
| JP2017515849A5 (enExample) | ||
| RU2023102211A (ru) | Схемы дозирования иммуноконъюгата anti-folr1 | |
| RU2015148884A (ru) | Эсликарбазепина ацетат и способы его применения |